Clinical Trial Design for Immune-Based Therapy of Hepatitis B Virus.
Semin Liver Dis
; 37(2): 85-94, 2017 05.
Article
em En
| MEDLINE
| ID: mdl-28564718
ABSTRACT
The treatment paradigm in hepatitis B virus is on the cusp of major development, with a multitude of novel agents undergoing testing for clinical efficacy. Such new immune therapies are urgently required for the treatment of chronic hepatitis B virus. The current direct antiviral therapies, although able to control viral replication and limit the progression to cirrhosis, require lifelong administration due to frequent viral rebound on treatment cessation, and immune modulation with interferon is only effective in a subpopulation of patients. Here the authors discuss novel agents in the pipeline along with whom and how best to utilize these immune therapies to achieve functional cure with defined treatment endpoints in chronic hepatitis B virus.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Antivirais
/
Projetos de Pesquisa
/
Vírus da Hepatite B
/
Ensaios Clínicos como Assunto
/
Hepatite B Crônica
/
Imunoterapia
Tipo de estudo:
Clinical_trials
Limite:
Humans
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article